Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEAMARK: Encorafenib, Cetuximab, and Pembrolizumab in Advanced Colorectal Cancer
NCT05217446Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Jul 2022
- Primary completion
- Jun 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 2 trial of encorafenib, KL-140 in colorectal cancer (CRC), sponsored by Pfizer. Started Jul 2022; status: active, not recruiting.
02
Drugs
encorafenibKL-140
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05217446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05217446.